Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
Nahid A. Qushmaq, General Supervisor Assistant for Medical Support Services, Consultant Adult Hematology of Thrombosis and Hemostasis, Head Of Research and Development Department at King Abdullah Medical Complex – Jeddah, shared a post on LinkedIn:
“One of the most valuable sessions I attended at ISTH 2026 was ‘Emerging Therapies in Thrombosis: Factor XI/XIa Inhibitors’, delivered by Dr. Jeffrey Weitz.
The session provided an excellent overview of the evolving role of FXI/FXIa inhibition in thrombosis prevention and highlighted the exciting potential of these novel agents to reduce thrombotic events while minimizing bleeding risk, making it one of the most promising next-generation anticoagulant strategies.
An insightful and thought-provoking session that reinforces how rapidly the field of thrombosis is advancing.”
Stay updates with Hemostasis Today.
-
Jul 27, 2026, 14:30William McKeown Elected Vice-President of the EHC
-
Jul 27, 2026, 13:45The Essentials of FFP Dosing and Monitoring – ICHCC
-
Jul 27, 2026, 13:27Antonio Lauletta: Distinguishing Sporadic and ICI-Related MG-Myositis Overlap
-
Jul 27, 2026, 13:15Satyam Arora: Welcoming the New ISBT Board and Looking Ahead
-
Jul 27, 2026, 13:03Jeff Parke: Why We Are Losing Viable Kidneys in Transit
-
Jul 27, 2026, 12:58George Hajishengallis: A New Era in Periodontal Disease Treatment
-
Jul 27, 2026, 12:54Elena Masselli: Can Statins Enhance Peginterferon Therapy in MPNs?
-
Jul 27, 2026, 12:32Sonia Elena Popovici: Redefining Hemorrhagic Shock Through Cellular and Molecular Insights
-
Jul 27, 2026, 12:24Abdul Mannan: Why Quantitative FXIII Testing Matters